Literature DB >> 22961987

The design and characterization of receptor-selective APRIL variants.

Fiona C Kimberley1, Almer M van der Sloot, Marco Guadagnoli, Katherine Cameron, Pascal Schneider, J Arnoud Marquart, Miranda Versloot, Luis Serrano, Jan Paul Medema.   

Abstract

A proliferation-inducing ligand (APRIL), a member of the TNF ligand superfamily with an important role in humoral immunity, is also implicated in several cancers as a prosurvival factor. APRIL binds two different TNF receptors, B cell maturation antigen (BCMA) and transmembrane activator and cylclophilin ligand interactor (TACI), and also interacts independently with heparan sulfate proteoglycans. Because APRIL shares binding of the TNF receptors with B cell activation factor, separating the precise signaling pathways activated by either ligand in a given context has proven quite difficult. In this study, we have used the protein design algorithm FoldX to successfully generate a BCMA-specific variant of APRIL, APRIL-R206E, and two TACI-selective variants, D132F and D132Y. These APRIL variants show selective activity toward their receptors in several in vitro assays. Moreover, we have used these ligands to show that BCMA and TACI have a distinct role in APRIL-induced B cell stimulation. We conclude that these ligands are useful tools for studying APRIL biology in the context of individual receptor activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961987      PMCID: PMC3481339          DOI: 10.1074/jbc.M112.406090

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.

Authors:  Claudia Bossen; Teresa G Cachero; Aubry Tardivel; Karine Ingold; Laure Willen; Max Dobles; Martin L Scott; Aris Maquelin; Elodie Belnoue; Claire-Anne Siegrist; Stéphane Chevrier; Hans Acha-Orbea; Helen Leung; Fabienne Mackay; Jürg Tschopp; Pascal Schneider
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

Review 2.  Protein design in biological networks: from manipulating the input to modifying the output.

Authors:  Almer M Van der Sloot; Christina Kiel; Luis Serrano; Francois Stricher
Journal:  Protein Eng Des Sel       Date:  2009-07-02       Impact factor: 1.650

3.  Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.

Authors:  Tomohiro Morishige; Yasuo Yoshioka; Hiroshi Inakura; Aya Tanabe; Xinglei Yao; Shin-ichi Tsunoda; Yasuo Tsutsumi; Yohei Mukai; Naoki Okada; Shinsaku Nakagawa
Journal:  Biomaterials       Date:  2010-02-01       Impact factor: 12.479

4.  TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.

Authors:  Yumiko Kanno; Daisuke Sakurai; Hidenori Hase; Hidefumi Kojima; Tetsuji Kobata
Journal:  J Recept Signal Transduct Res       Date:  2010-04       Impact factor: 2.092

Review 5.  APRIL in B-cell malignancies and autoimmunity.

Authors:  Fiona C Kimberley; Jan Paul Medema; Michael Hahne
Journal:  Results Probl Cell Differ       Date:  2009

6.  The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking.

Authors:  Fiona C Kimberley; Liesbeth van Bostelen; Katherine Cameron; Gijs Hardenberg; J Arnoud Marquart; Michael Hahne; Jan Paul Medema
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

7.  DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.

Authors:  Vicente Tur; Almer M van der Sloot; Carlos R Reis; Eva Szegezdi; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

8.  Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains.

Authors:  Lee Kim Swee; Karine Ingold-Salamin; Aubry Tardivel; Laure Willen; Olivier Gaide; Manuel Favre; Stéphane Demotz; Marja Mikkola; Pascal Schneider
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

9.  Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion.

Authors:  Franziska B Mullauer; Jan H Kessler; Jan Paul Medema
Journal:  Apoptosis       Date:  2009-02       Impact factor: 4.677

10.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

View more
  7 in total

1.  Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Abby Jones Weldon; Ioana Moldovan; Marven G Cabling; Elvin A Hernandez; Sheri Hsu; Jennifer Gonzalez; Andrea Parra; Abigail Benitez; Nasim Daoud; Keith Colburn; Kimberly J Payne
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

2.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

3.  An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

Authors:  Lydia Lee; Benjamin Draper; Neil Chaplin; Brian Philip; Melody Chin; Daria Galas-Filipowicz; Shimobi Onuoha; Simon Thomas; Vania Baldan; Reyisa Bughda; Paul Maciocia; Eva Kokalaki; Margarida P Neves; Dominic Patel; Manuel Rodriguez-Justo; James Francis; Kwee Yong; Martin Pule
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

4.  Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.

Authors:  Sonia Schuepbach-Mallepell; Dolon Das; Laure Willen; Michele Vigolo; Aubry Tardivel; Luc Lebon; Christine Kowalczyk-Quintas; Josquin Nys; Cristian Smulski; Timothy S Zheng; Klaus Maskos; Alfred Lammens; Xuliang Jiang; Henry Hess; Seng-Lai Tan; Pascal Schneider
Journal:  J Biol Chem       Date:  2015-05-07       Impact factor: 5.157

5.  Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia.

Authors:  Christine Kowalczyk-Quintas; Sonia Schuepbach-Mallepell; Michele Vigolo; Laure Willen; Aubry Tardivel; Cristian R Smulski; Timothy S Zheng; Jennifer Gommerman; Henry Hess; Jacques-Eric Gottenberg; Fabienne Mackay; Olivier Donzé; Pascal Schneider
Journal:  J Biol Chem       Date:  2016-07-22       Impact factor: 5.157

6.  Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Authors:  Valeria Lascano; Marco Guadagnoli; Jan G Schot; Dieuwertje M Luijks; Jeroen E J Guikema; Katherine Cameron; Michael Hahne; Steven Pals; Erik Slinger; Thomas J Kipps; Marinus H J van Oers; Eric Eldering; Jan Paul Medema; Arnon P Kater
Journal:  Blood       Date:  2013-10-07       Impact factor: 22.113

7.  Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Authors:  Gözde Isik; Kwinten Sliepen; Thijs van Montfort; Rogier W Sanders
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.